Crucial Role of the H11-H12 Loop in Stabilizing the Active Conformation of the Human Mineralocorticoid Receptor
Chantal Hellal-Levy,
Jérôme Fagart,
Anny Souque,
Jean-Marie Wurtz,
Dino Moras and
Marie-Edith Rafestin-Oblin
INSERM U478 (C.H.-L., A.S., M.-E.R.-O.) Faculté de
médecine Xavier Bichat Institut fédératif de
recherche 02 B.P. 416, 75780 Paris Cédex 18, France
Institut de Génétique et de Biologie
Moléculaire et Cellulaire (J.F., J.-M.W., D.M.) B.P.
163, 67404 Illkirch Cédex CU de Strasbourg, France
 |
ABSTRACT
|
---|
The crystal structures of ligand-free and
agonist-associated ligand-binding domain (LBD) of nuclear receptors
(NRs) reveal that the amphipathic helix H12 is folded back toward the
LBD core in the agonist-associated conformation, allowing the binding
of coactivators. We used alanine scanning mutagenesis to explore the
role of the residues of the loop connecting H11 and H12 in the
activation of the human mineralocorticoid receptor (hMR), a member of
the NRs family. H950A retained the ligand binding and transcriptional
activities of the wild-type receptor and interacted with coactivators.
In contrast F956A had no receptor functions. Aldosterone bound to the
mutant hMRs (L952A, K953A, V954A, E955A, P957A) with nearly the same
affinity as to the wild- type receptor and caused a receptor
conformational change in these mutant hMRs as it does for the
wild-type receptor. But the aldosterone-induced transcriptional
activity of the mutant hMRs was lower (L952A, E955A, P957A) than that
of the wild-type receptor or completely abolished (K953A, V954A) and
their interaction with coactivators was impaired (E955A) or suppressed
(L952A, K953A, V954A, P957A). In the light of a hMR-LBD model based on
the structure of the progesterone-associated receptor-LBD, we propose
that the integrity of the H11-H12 loop is crucial for folding the
receptor into a ligand-binding competent state and for establishing the
network of contacts that stabilize the active receptor conformation.
 |
INTRODUCTION
|
---|
The human mineralocorticoid receptor (hMR), which mediates the
physiological action of aldosterone, belongs to the nuclear receptor
(NR) superfamily (1, 2, 3, 4). These receptors have a common modular
structure with three major functional domains. The most divergent
module is the N-terminal A/B region, which contains the constitutive
transactivation function AF-1. The central DNA-binding domain (DBD) is
highly conserved and composed of two zinc fingers that are involved in
DNA binding and receptor dimerization. The ligand-binding domain (LBD)
lies in the C-terminal region and takes part in several functions,
including nuclear localization, interaction with the heat shock protein
90 (hsp90), homo- and/or hetero-dimerization, and a ligand-dependent
activation function AF-2.
The precise mechanisms whereby transcription is stimulated remain
unknown. In the absence of hormone, steroid receptors are associated
with an inhibitory multiprotein complex composed of hsp90, hsp70, p59,
and other factors (5). The binding of the steroid to the hMR induces a
change in the receptor conformation that is believed to lead to the
dissociation of the multiprotein complex formed with receptor (6, 7).
Recent studies have identified two related proteins, a nuclear receptor
corepressor (N-CoR) and a silencing mediator for the retinoid and
thyroid-hormone receptors (SMRT), that mediate the repression of
transcription by thyroid hormone receptor (TR) and retinoic acid
receptor (RAR) (8, 9). The nuclear hormone receptors that interact with
N-CoR and SMRT now include other members of the NR superfamily, such as
COUP-TF, and the thiazolidinedione-peroxisome proliferator-activated
receptor
(PPAR
) (10, 11).
Several crystal structures of NR-LBDs have been described: the
ligand-free form (apo receptor) of the retinoid X receptor
(RXR
)
and PPAR
, the ligand-bound form (holo receptor) of
all-trans-retinoic acid receptor
(RAR
), TR
, ER
,
PR, and PPAR
(12, 13, 14, 15, 16, 17, 18). All these NR-LBDs have a common fold with 11
to 12
-helices (numbered H1-H12) and one ß-sheet arranged as an
antiparallel
-helical "sandwich" in a three-layer structure
(19). Ligand binding causes the LBD to adopt a more compact structure;
the helix H11 is repositioned in the continuity of H10 and the helix
H12, that comprises the autonomous activating domain (AF-2AD), is
folded back toward the LBD core. The repositioning of the activation
helix H12, together with additional structural changes such as bending
of H3, brings it into a distinct receptor environment, thus creating an
interface suitable for NR coactivator binding (20). Many coactivators
interacting with the nuclear receptors in a ligand-dependent manner
have been identified to date. These include steroid
receptor-coactivator 1 (SRC-1), transcriptional intermediary factor II
(TIF-II)/GRIP-1, and 140-kDa receptor-interacting proteins (RIP-140),
TIF1, and CBP/p300 (10, 11).
Because agonist-induced repositioning of the helix 12 is crucial to
bring steroid receptors in a suitable conformation for productive
interaction with transcriptional machinery, the question arises whether
the extended region connecting the helices H11 and H12 (H11-H12 loop),
which is highly conserved among steroid receptors, plays a role in the
intramolecular process(es) of MR activation. A detailed mutagenesis
analysis of the hMR H11-H12 loop was therefore carried out. The
ligand-binding properties and transcriptional activities of the mutant
hMRs were measured. Their ability to interact with coactivators was
assessed as well as their conformational states. In the light of a
three-dimensional model of the hMR-LBD, we propose that H11-H12 loop is
required to fold the hMR into a ligand-binding competent state and to
stabilize the active receptor conformation.
 |
RESULTS
|
---|
Steroid Binding to Mutant hMRs
The sequence alignment of the H11-H12 loop from MRs of
numerous species and also from hGR, hAR, hER
, and hPR is presented
in Fig. 1
. The residues of the H111-H12
loop are highly conserved among MRs. hGR has one residue and hER
three residues less than the hMR, whereas the H11-H12 loops in hAR and
hPR have the same length as in the hMRs. Residues of the hMR H11-H12
loop were replaced by alanine and the corresponding mutant receptors
referred to as H950A, L952A, K953A, V954A, E955A, F956A, and P957A.
Wild-type and mutant hMRs were expressed in vitro and tested
for their expression level and ability to bind aldosterone. As observed
in Fig. 2A
, similar amounts of the
wild-type and mutant hMRs were synthesized according to the protein
band intensity with a molecular mass of 110 kDa. H950A, L952A and E955A
retained the aldosterone binding capacity of the wild-type receptor
(Fig. 2B
). K953A, V954A, and P957A displayed 5075% of the
aldosterone binding capacity. In contrast F956A was unable to bind
aldosterone (Fig. 2B
). Moreover, the mutant hMRs transiently expressed
in COS-7 cells were tested for their ability to bind aldosterone.
L952A, K953A, V954A, and P957A displayed 3565% of the aldosterone
binding capacity. H950A and E955A retained 100% of the aldosterone
binding capacity whereas F956A has completely lost this function (data
not shown).

View larger version (50K):
[in this window]
[in a new window]
|
Figure 1. Sequence Alignment of Amino Acids of the H11-H12
Loop Region of Steroid Receptors
The alignment includes MRs from many organisms plus hGR, hAR,
hER , and hPR. The abbreviations are h, Homo sapiens;
r, Rattus norvegicus; t, Tupaia belangeri; x,
Xenopus laevis. The positions of the ends of the helices H11
and H12 are illustrated below the alignment. The
numbering above the alignment is for hMR. Identical residues
in the MR family are in gray. Those similar in all sequences
are boxed. The figure was prepared using ALSCRIPT (54 ).
|
|

View larger version (52K):
[in this window]
[in a new window]
|
Figure 2. Binding of Aldosterone to the Wild-Type and Mutant
hMRs
A, [35S]-labeled wild-type and mutant
hMRs were synthesized in vitro and analyzed by
electrophoresis in a 12.5% (wt/vol) polyacrylamide gel. The molecular
mass markers are indicated on the left-hand side of the
figure. B, The wild-type and mutant hMRs were synthesized in
vitro. The lysate was diluted 2-fold with TEGWD buffer and
incubated with 10 nM
[3H]-aldosterone for 30 min at 20 C. Bound and
free steroids were separated by the dextran-charcoal method.
Nonspecific binding was measured in a parallel experiment without any
receptor expressing vector. Results are given as specific
[3H]-aldosterone binding compared with 100%
binding to wild-type hMR.
|
|
The aldosterone-binding properties of the mutant hMRs expressed
in vitro was further characterized by measuring the
dissociation constant at equilibrium (Kd) and the
half-life time (t1/2) of the hormone-receptor
complexes. Aldosterone bound to L952A, K953A, V954A, E955A, and P957A
with an affinity 2- to 5-fold lower than that of the wild-type receptor
(Table 1
). Aldosterone dissociated from
L952A, K953A, and P957A much more rapidly (t1/2
values of 310 min) than from the wild-type receptor (120 min) (Table 1
) and the aldosterone-E955A complex was characterized by a half-life
time of 42 min.
As the heat shock protein hsp90 plays a crucial role to fold the
receptor into a ligand binding-competent state (21), we compared the
sedimentation profile of F956A with that of the wild-type receptor. It
has been reported that the hsp90-MR complexes sedimented on sucrose
gradient in the 810S region, whereas upon hsp90 dissociation the
receptor sedimented in the 4S region (22). The ligand-free wild type
and F956A were synthesized in vitro in the presence of
35S methionine and analyzed by sucrose gradient
centrifugation. F956A sedimented in the 810S region as did the
wild-type receptor (Fig. 3
), suggesting
that replacement of Phe956 by an alanine does not prevent the
hsp90-receptor interaction.

View larger version (26K):
[in this window]
[in a new window]
|
Figure 3. Sedimentation Gradient Analyses of Mutant hMRs in
Ligand-Free Conditions
[35S]-MR, and F956A were synthesized in
vitro (0.1 ml), were layered onto a 520% sucrose gradient
equilibrated in TEGWD buffer. Gradients were centrifuged for 1 h,
45 min at 365,000 x g in a VTi 65.2 rotor at 4 C.
Collected fractions were analyzed by electrophoresis on a 7.5%
(wt/vol) polyacrylamide gel. The band corresponding to the intact or
mutant protein was scanned and quantified. The signal intensity was
plotted against the relative migration coefficient (Rf). The
sedimentation markers were aldolase (A, 7.9S) and BSA (4.6S).
|
|
Thus, substitution of the H11-H12 loop residues does not modify
the expression level of the mutant hMRs compared with the wild-type
receptor. Replacement of Phe956 by alanine induced a complete loss of
the receptor ligand-binding capacity that was not due to the inability
of this mutant hMR to interact with hsp90. Replacement of His950 and
Glu955 by alanine does not alter the ligand-binding capacity of the
receptor whereas replacement of Leu952, Lys953, Val954, and Pro957 led
to a decrease of this function. Interestingly, an increase of the
aldosterone dissociation rate from L952A, K953A, E955A, and P957A was
observed, whereas the aldosterone dissociation constant at equilibrium
for these mutant hMRs was of the same order of magnitude as that
observed for the wild-type receptor.
Conformation Analysis of the Mutant hMRs by Limited Proteolysis
Assays
We investigated whether replacement Phe956 by alanine
induced a change in the receptor conformation leading to the lack of
aldosterone binding. The sensitivity of F956A to chymotrypsin was
examined and compared with that of the wild type. The
35S-labeled wild-type hMR and F956A synthesized
in vitro were incubated in ligand-free conditions with 15
µg/ml chymotrypsin for 530 min, and the digestion products were
analyzed by SDS-PAGE (Fig. 4
). The
wild-type receptor and F956A were both synthesized at the same level
(Fig. 4
, lanes 1 and 6). Two major fragments corresponding to molecular
masses of 27 and 30 kDa were generated from both the wild-type hMR and
F956A, but the abundance of the two fragments differed. After 5 min
chymotrypsin treatment, the intensity of the 30-kDa fragment generated
from the wild-type receptor was higher than that of the 27-kDa fragment
(Fig. 4
, lane 2), and the two fragments were completely digested after
a 30-min proteolysis (Fig. 4
, lane 6). In the case of F956A, the
intensity of the 30-kDa fragment was lower than that of the 27-kDa
fragment (Fig. 4
, lane 8), and the 30- and 27-kDa fragments were
completely digested after 15 and 30 min proteolysis, respectively (Fig. 4
, lanes 10 and 12). The 30-kDa fragment corresponds to the sequence
Ile711-Lys984, which contains the C-terminal part of the hinge region
and the entire LBD of the receptor (7). The 27-kDa fragment has not
been identified. Proteolysis experiments performed with a truncated
hMR, lacking the A/B domain, generated the 30- and 27-kDa fragments,
suggesting that the 27-kDa fragment did not encompass the A/B region.
Altogether these findings revealed an increase in the receptor
sensitivity to proteolysis upon Phe956 substitution, suggesting a
change in the receptor compaction.

View larger version (53K):
[in this window]
[in a new window]
|
Figure 4. Chymotrypsin Proteolysis of the Ligand-Free
Wild-Type and F956A
[35S]-labeled hMR and F956A were expressed in
vitro and incubated at 20 C without or with 15 µg/ml
chymotrypsin for 530 min. The digestion products were analyzed by
electrophoresis in a 12.5% (wt/vol) polyacrylamide gel and
autoradiographed. The molecular mass markers are indicated on the
left-hand side of the figure.
|
|
Binding of aldosterone to the wild-type hMR caused a change in
the receptor conformation revealed by an increase in the resistance of
the 30-kDa fragment to chymotrypsin (7). As aldosterone bound to L952A,
K953A, V954A, and P957A, the ability of aldosterone to modify the
conformation of these mutant hMRs was examined. Treatment of
ligand-free hMR with 150 µg/ml chymotrypsin for 10 min led to a
complete digestion of the receptor (Fig. 5
, lanes 2). When the wild-type and
mutant hMRs (L952A, K953A, V954A, and P957A) were first incubated with
aldosterone and then with chymotrypsin for 10 min treatment, a 30-kDa
fragment was detected (Fig. 5
, lanes 37). The 30-kDa fragment
generated from the mutant hMRs was partially (L952A) or completely
(K953A, V954A, and P957A) digested after 60 min chymotrypsin treatment,
whereas 30-kDa fragment generated from the wild-type receptor was
highly resistant (Fig. 5
, lanes 812). These results suggest that
replacement of Leu952, Lys953, Val954, and Pro957 by alanine does not
prevent the aldosterone-induced compaction of the receptor.
Nevertheless, these aldosterone-mutant hMRs complexes are less
resistant to proteolysis than the wild-type receptor associated with
aldosterone, suggesting a different or less stable conformation of
these mutant receptors compared with the wild-type hMR.

View larger version (43K):
[in this window]
[in a new window]
|
Figure 5. Chymotrypsin Proteolysis of the Free hMR and
Aldosterone-Bound Wild-Type and Mutant hMRs
[35S]-labeled hMR and mutant hMRs L952A, K953A, V954A,
and P957A were produced in vitro and incubated or not
with 10-7 M of aldosterone. The resulting
complexes were incubated at 20 C without or with 150 µg/ml
chymotrypsin for 10 and 60 min. The digestion products were analyzed by
electrophoresis in a 12.5% (wt/vol) polyacrylamide gel and
autoradiographed. The molecular mass markers are indicated on the
left-hand side of the figure.
|
|
Transcriptional Activation by Mutant hMRs
We examined the activity of the wild-type and mutant hMRs
in cis-trans cotransfection assays. The mutant and wild-type
cDNA were transiently transfected into COS-7 cells together with a
reporter plasmid containing the mouse mammary tumor virus (MMTV)
promoter upstream of the luciferase gene. The activity of the mutant
hMRs in response to 10-6 M
aldosterone is reported in Fig. 6A
. The
aldosterone induced-activity of H950A and E955A was nearly the same as
that of the wild-type hMR. L952A and P957A displayed approximately 50%
of the wild-type receptor activity; in contrast, K953A, V954A, and
F956A have completely lost the receptor activity (Fig. 6A
).
Dose-response curves were also generated by adding increasing
concentrations of aldosterone to transfected cells (Fig. 6B
).
Aldosterone increased the luciferase activity of the wild-type hMR in a
dose-dependent manner with an ED50 value of
approximately 10-10 M.
Replacement of His950 by alanine did not modify the aldosterone-induced
transactivation activity of hMR, and replacement of Glu955 by alanine
induced a shift in the dose-response curve of the aldosterone-induced
luciferase activity toward higher concentrations with an
ED5O value of approximately
10-9 M. The aldosterone-
mediated activities of L952A, K953A, V954A, and P957A were low
(Fig. 6B
). Progesterone, a potent mineralocorticoid antagonist (23),
was able to inhibit the aldosterone-induced activity of H950A and E955A
by 80%, as it does for the wild-type hMR (data not shown). Thus,
except H950A, which retained the transcriptional activity of the
wild-type receptor, all the other mutant hMRs, within the H11-H12 loop,
displayed a lower transcriptional activity, suggesting that this loop
is involved in the hMR activation process.

View larger version (31K):
[in this window]
[in a new window]
|
Figure 6. Transactivation Properties of Wild-Type and Mutant
hMRs in Response to Aldosterone
COS-7 cells were transfected with wild-type or mutant hMRs expression
vectors, pFC31luc as reporter plasmid, and a ß-galactosidase internal
reporter to correct for transfection efficiency. A, Before
harvesting, cells were treated for 24 h with aldosterone at
10-6 M. Transactivation
was determined by luciferase activity, normalized to the internal
ß-galactosidase control, and is expressed as percent of wild-type
activity at 10-6 M. Each
point is the mean ± SEM of three separate
experiments. B, Transactivation properties of wild-type and
mutant hMRs in response to increasing concentrations of aldosterone
were determined by measuring luciferase activity, normalized to the
internal ß-galactosidase control, and expressed as percent of
wild-type activity at 10-9
M aldosterone. Each point is the mean ±
SEM of three separate experiments.
|
|
Interaction of Wild-Type and Mutant hMRs with Coactivators in
Vitro
Numerous reports have stated that coactivator factors are required
for the NRs full activity (10, 11). We therefore examined, by
glutathione-S-transferase (GST) pull-down assays, whether
the wild type and mutant hMRs were able to recruit SRC-1, RIP-140, or
TIF1
(24, 25, 26). The wild-type hMR did not interact with coactivators
in the absence of ligand (Fig. 7A
, lanes
3, 6, and 9) or in the presence of progesterone (Fig. 7A
, lanes 5, 8,
and 11). Incubation of hMR with aldos-terone promoted the
interaction of the receptor with coactivators (Fig. 7A
, lanes 4, 7, and
10). Our results are consistent with those observed with GRIP1 and
SCR-1 for the rat MR (27, 28) and other NRs indicating that the
receptor-coactivator interaction is agonist dependent (10, 11). As
observed for the wild-type hMR, the ligand-free H950A, K953A, and E955A
did not interact with hTIF1
(Fig. 7B
, lanes 1, 3, and 5). In the
presence of aldosterone, H950A interacted with hTIF1
(Fig. 7B
, lane
2), and a weak interaction was detected for E955A (Fig. 7B
, lane 6).
hTIF1
did not interact with aldosterone-associated K953A (Fig. 7B
, lane 4), and no interaction of L952A, V954A, and P957A with hTIF1
was detected (data not shown). The interaction profile of the mutant
hMRs with RIP140 and SRC-1 was the same as that observed with hTIF1
(data not shown). Altogether, these results showed that, with the
exception of H950A and E955A, all the mutant hMRs have lost their
ability to bind coactivators.

View larger version (60K):
[in this window]
[in a new window]
|
Figure 7. Interaction of SRC-1, RIP-140, and hTIF1 with
Wild-Type and Mutant hMRs
A, GST fusion proteins, which previously had been coupled to
Sepharose glutathione beads, were incubated with
[35S]methionine-labeled wild-type hMR in the
absence (lanes 3, 6, and 9) or presence of 1 µM
aldosterone (lanes 4, 7, and 10) or 1 µM
progesterone (lanes 5, 8, and 11) for 10 min at 20 C. The glutathione
Sepharose beads were washed and boiled in Laemmli buffer. The samples
were then analyzed by SDS-PAGE followed by autoradiography. As control,
incubation with GST alone (lane 2) and 1/10 of the receptor input used
in the assay (lane 1) are shown. B, Interaction of hTIF1 with mutant
hMRs (H950A, K953A, and E955A). The interaction assay was performed in
the absence of hormone (lanes 1, 3, and 5) and with 1
µM aldosterone (lanes 2, 4, and 6) for 10 min
at 20 C. The washed glutathione Sepharose beads were boiled in Laemmli
buffer, and samples were analyzed by SDS-PAGE followed by
autoradiography. The wild-type and mutant hMRs are expressed at the
same level (data not shown).
|
|
Three-Dimensional Organization of the H11-H12 Loop
The hMR-LBD homology model, generated using the crystallographic
structure of the hPR-LBD as a template, showed the N-terminal part of
the loop to be organized as a short helix (from Ser949 to Ala951), with
the remainder in an almost extended conformation (Fig. 8
). The polar residues face the solvent,
whereas the hydrophobic ones are buried and point toward the core of
the protein. Phe956 is within the region delimited by the helices H3,
H11, and H12 and forms van der Waal contacts with Asn770 (H3), Phe946
(H11), Ser949 and Val954 (H11-H12 loop), Leu960, Val961 and Ile964
(H12), and the aldosterone C21-hydroxyl group (3, 2 Å) (Fig. 9A
). Val954 is deeply buried (<10% of
solvent accessibility) and is in close contact with Glu763, Leu766,
Ser767 and Asn770 (H3), Leu952 and Phe956 (H11-H12 loop) (Fig. 9B
).
Leu952 is less well buried (24% accessibility) than Val954 and is
close to Thr945 (H11) and Val954 (H11-H12 loop) (Fig. 9B
). The two
charged residues of the H11-H12 loop (Lys953 and Glu955) could form
salt bridges with Glu763 and Arg771, respectively, two residues of H3
(Fig. 9B
). As in the hPR crystal structure, the backbone oxygen atom of
Glu955 forms a strong hydrogen bond with the Asn770 amide group (Figs. 8
and 9A
). From this model, it appeared that there are numerous
contacts between the H11-H12 loop residues and also between the
residues of this loop and residues of H3, H11, and H12.

View larger version (59K):
[in this window]
[in a new window]
|
Figure 8. Aldosterone Docking in the hMR Ligand-Binding
Pocket
Diagram showing the overall fold of the hMR-LBD surrounding aldosterone
with the -helices drawn as ribbons and the
ß-strands as arrows. Only the residues of the H11-H12
loop and those making hydrogen bonds with aldosterone are shown. The
figure was produced with SETOR (52 ).
|
|

View larger version (50K):
[in this window]
[in a new window]
|
Figure 9. Organization of the hMR H11-H12 Loop Residues
A, Close-up view of the Phe956 van der Waals contacts and the hydrogen
bond network of Asn770. B, Close-up view of the Leu952 and Val954 van
der Waals contacts and of the salt bridges. The figures were produced
with SETOR (55 ).
|
|
 |
DISCUSSION
|
---|
Studies on the crystal structures and functions of several NRs
(20) have revealed that the position of helix H12, which harbors the
ligand-dependent activation function, plays a major role in receptor
activity. Binding of an agonist to its receptor results in a precise
positioning of H12, placing it on the ligand-binding pocket, where it
contributes to the area that interacts with coactivators. Our
site-directed mutagenesis on the role of the loop connecting the
helices H11 and H12 in the activation of the hMR shows that Phe956 is
required for hMR to adopt a conformation competent for ligand binding
and that numerous residues in this loop are critical for stabilizing
the active receptor conformation.
Replacement of Phe956 by alanine within the hMR causes a complete loss
of ligand binding and transcriptional activity. The hMR homology model,
based on the structural data of the progesterone-associated hPR,
revealed that the 21-hydroxyl group of aldosterone is in a
favorable position to make van der Waals contacts with Phe956. But it
is unlikely that the loss of aldosterone binding capacity upon Phe956
substitution is due solely to the absence of this contact, since
progesterone, which lacks the 21-hydroxyl group, is also unable to bind
F956A (data not shown). The inability of F956A to bind agonist and
antagonist ligands is not due to a lack of interaction with hsp90 since
F956A sedimented at 810S as hsp90-receptor complexes (21). The loss
of ligand binding capacity upon Phe956 substitution is due to a change
in the receptor conformation, as F956A displays a high sensitivity to
chymotrypsin compared with the wild-type receptor. Altogether, these
results suggest that the residue Phe956 is essential to fold the hMR
into a ligand binding competent state.
Replacement of His950 by alanine does not modify the aldosterone
binding and transcriptional activities of the wild-type receptor. In
contrast, replacement of the other H11-H12 loop residues decreased
(Leu952, Glu955, Pro957) or completely abolished (Lys953, Val954) the
receptor activity without notably modifying the affinity of the
receptor for aldosterone. The different sensitivities of ligand binding
and transcriptional activities to substitution of an H11-H12 loop
residue have been reported for other steroid receptors. A naturally
occurring mutant androgen receptor, in which Val889 (V954 in hMR) is
replaced by a methionine, is nearly completely insensitive to
androgens, whereas it has a normal binding affinity for androgens (29).
Similarly, a mutant GR, in which Ile747 (Val954 in hMR) is replaced by
threonine, can bind dexamethasone like the wild-type receptor, but high
dexamethasone concentrations are needed to stimulate the
transactivation function (30).
The first step after aldosterone binding to the receptor is a change in
the receptor conformation, revealed by an increase in the resistance of
the receptor to proteolysis (7). The binding of aldosterone to L952A,
K953A, V954A, and P957A increases the resistance of the receptor to
chymotrypsin, suggesting that aldosterone bound to these mutant
hMRs causes a change in receptor compaction in a way similar to the
effect of aldosterone bound to the wild-type receptor. But, as
aldosterone dissociates more rapidly from mutant hMRs than from the
wild-type receptor, it is less effective in protecting these mutant
hMRs against proteolysis than the wild-type receptor. Thus, the ability
of aldosterone to protect mutant hMRs against proteolysis depends
upon the stability of the aldosterone-receptor complex.
There have been several reports that coactivators interact with NRs
when receptors are transcriptionally active (31, 32, 33, 34). The introduction
of a mutation into the TRß-H12 (35), the vitamin D receptor-H12 (36),
and the ER-H3 (37) causes an alteration in the NR activity together
with an impaired interaction with coactivators. The loss of these two
functions upon mutation of residues within the helices H12 or H3 is not
surprising, given the model proposed from structural data that compares
the ligand-induced receptor transconformation to a mouse trap
mechanism, by which structural changes such as bending of helix H3,
bring the helix H12 into a distinct receptor environment creating the
areas for coactivator binding. Furthermore, analysis of the structure
of agonist-associated PPAR and hER
LBD complexed with a peptide
encompassing the coactivator LXXLL region shows that this peptide is
bound, in a
-helical conformation, by a hydrophobic groove formed by
residues from helices H3, H4, H5, and H12 (38, 39). The present study
shows that aldosterone-associated-hMR interacts with SRC-1 RIP140 and
hTIF1
. In contrast, neither ligand-free nor
antagonist-associated-hMR bind these coactivators, indicating that the
hMR-coactivator interaction is agonist dependent. Those mutant hMRs
that retain the full transcriptional activity interact with
coactivators, as it is observed for H950A. The poor ability of E955A to
recruit coactivators is consistent with the lower sensitivity of this
mutant hMR (ED50 10-9
M) compared with that of the wild- type receptor
(10-10 M). The inability of L952A,
K953A, V954A, and P957A to recruit coactivators, whereas L952A and
P957A display 50% of the wild-type receptor activity, might be due to
the rapid dissociation of aldosterone from these mutant hMRs and/or to
poor receptor-coactivator contacts resulting from a modification of the
aldosterone-associated-hMR conformation.
The homology model of the hMR LBD reveals numerous contacts in the
H11-H12 region that might help to stabilize the aldosterone
associated-hMR conformation. There are van der Waals contacts between
the hydrophobic residues of the H11-H12 loop (Val 954 with Leu952 and
Phe956) and also between residues of the loop and the nearby amino
acids of H3, H11, and H12. In addition, the two polar residues of the
loop (Lys953 and Glu955) are in suitable positions to make salt bridges
with two residues of H3 (Glu763 and Arg771). These contacts may help
anchor the H11-H12 loop to helix H3, as mutation of these residues
reduces (Glu955) or abolishes (Lys953) receptor activity without
preventing the ligand binding and resistance to proteolysis.
Furthermore, the oxygen atom of the Glu955 main chain forms a strong
hydrogen bond with Asn770 in helix 3, a residue that is critical in the
binding of C21-hydroxylated agonists such as aldosterone (40). This
network of contacts is essential for the transition from the
ligand-free inactive to the liganded active receptor state. The
structure of the ligand-free hMR is unknown: it could be similar to
that of the ligand-free RXR
(12), in which helix H11 obstructs the
ligand binding cavity, and the H11-H12 loop and H12 point away from the
LBD core. The residues of the H11-H12 loop might be compared with a zip
fastener, in which each residue of the H11-H12 loop is a link, which
helps to promote the precise positioning of H12. It is likely that the
accommodation of the receptor around aldosterone is a rate limiting
step, as proposed by Ribeiro et al. (41) for TRß, which
depends greatly upon the integrity of the H11-H12 loop residues.
The results described here point out the role of the H11-H12 loop in
stabilizing the inactive ligand-free and active aldosterone-associated
hMR conformation states. With the help of other factors, such as hsp90,
the loop H11-H12 maintains the receptor in an open state able to bind
agonist and antagonist ligands. It is also essential for establishing
the network of contacts required for ordering the activation helix H12
allowing coactivators recruitment. The similarity of the overall
organization of NRs and the existence of mutations in other NRs with
similar effects on the receptor activation led us to propose that the
H11-H12 loop is involved in producing the active state in the other
nuclear receptors.
 |
MATERIALS AND METHODS
|
---|
Chemicals
[1,2-3H]aldosterone (4060 Ci/mmol),
[35S]methionine (1,000 Ci/mmol) and
[14C]-labeled low range protein molecular mass
markers were purchased from Amersham Pharmacia Biotech
(Les Ulis, France). Nonradioactive aldosterone, progesterone, trypsin,
and chymotrypsin were obtained from Sigma (St. Louis, MO.
Entensify Universal Autoradiography Enhancer was obtained from Du Pont-New England Nuclear (Boston, MA). Purified oligonucleotides
and products for cell culture were from Life Technologies, Inc. (Cergy Pontoise, France). The protection mammalian
transfection system, the TNT T7-coupled rabbit reticulocyte lysate
system and isopropyl ß-D-thiogalactoside were purchased
from Promega Corp. (Charbonnières, France). To avoid
steroid adsorption, steroid solutions prepared in ethanol were dried
and the steroids were suspended in 50% (vol/vol) polyethylene glycol
300 prepared in TEG buffer (20 mM Tris-HCl, 1
mM EDTA, and 10% glycerol, pH 7.4) to give a final
concentration of 5% in the lysate.
Expression and Reporter Constructs
The plasmid pchMR was constructed by excising a 3.6-kb
HindIII-HindIII fragment containing the entire
coding sequence of the hMR gene and about 270 bp and 400 bp of the 5'-
and 3'-untranslated regions from plasmid 3750 (1). This fragment was
subcloned into the expression vector pcDNA3 (Invitrogen,
NV leek, The Netherlands). pFC31Luc, which contains the MMTV promoter
driving the luciferase gene, was obtained from H. Richard-Foy (LMBE,
Toulouse, France) (42).
Site-Directed Mutagenesis
Site-specific mutagenesis of the hMR was performed by the method
of Nelson and Long (43). The mutant hMR fragments were obtained by PCR
amplification using GeneAmp (Perkin-Elmer Cetus, Norwalk,
CT). Four primers were used: a reverse hybrid primer downstream of an
AflII enzyme restriction site, composed of a nucleotide
sequence complementary to the cDNA reverse strand and a single 5'-20
nucleotide sequence: (5'-GGGGTACTAGTAACCCGGGCACCTCTGCCA GCTCTGCCC-3'),
a forward primer upstream of a BpU1102I enzyme restriction site:
(5'-ACGAAGTGTTTCTACTGGATC-3'), a reverse primer of identical sequence
to the single sequence 5'-20 nucleotide: (5'-GGGGTACTAGTAACCCGGGC-3'),
and a forward mutagenic primer with base mismatch was used as
follows:
H950A:5'-ACCTTCCGAGAGTCCGCTGCGCTGAAG GTA-3',
L952A: 5'-TCCCATGCGGCGAAGGTAGAGTTCCCC-3',
K953A: 5'-TCCCATgCgCTGgCggTAgAgTTCCC C-3',
V954A: 5'-TCCCATgCgCTgAAggCAgAgTTCCCC-3',
E955A: 5'-CTgAAGGTAGCGTTCCCCGCAATGCTG-3',
F956A: 5'-CTGAAGGTAGAGGCCCCCGCAATGCTG-3'
P957A: 5'-CTgAAggTAgAgTTCgCCgCAATgCTg-3').
The amplified products were digested with BpU1102 and
AflII, purified by agarose gel electrophoresis, subcloned
into the BpU1102 and AflII sites pchMR vector and
transformed into electrocompetent JM109 cells. The presence of the
specific mutation and the lack of random mutations were checked by DNA
sequence analysis (Genome Express, Grenoble, France).
Cell Culture and Transfection
COS-7 cells were cultured in DMEM (Life Technologies, Inc., Cergy Pontoise, France) supplemented with 10%
heat-inactivated FCS, 2 mM glutamine, 100 IU/ml penicillin,
and 100 µg/ml streptomycin in a humidified atmosphere with 5%
CO2. Cells were maintained in the medium
supplemented with 10% charcoal-stripped FCS 4 h before and
thoughout the transfection procedure. Cells were transfected by the
phosphate calcium precipitation method (Promega Corp.
system). The phosphate solution, prepared for six-well trays, contained
5 µg of one of the receptor expression vectors (wild-type or mutant
pchMR), 10 µg pFC31Luc (42) that contained the MMTV promoter driving
the luciferase gene, and 5 µg pSVß, including the gene coding for
ß-galactosidase. The steroids to be tested were added to the cells
12 h after transfection and incubation continued for 24 h.
Cell extracts were then prepared and assayed for luciferase (44) and
ß- galactosidase activities (45). To standardize for transfection
efficiency, the relative light units, obtained in the luciferase assay,
were divided by the optical density obtained in the ß-galactosidase
assay.
Coupled Cell-Free Transcription and Translation
Plasmids (1 µg) containing cDNA coding for the full-length hMR
(1) or mutant hMRs were transcribed using T7 RNA polymerase, and the
mRNA was simultaneously translated in rabbit reticulocyte lysate for
1 h at 30 C according to the manufacturers instructions. The
reactions were conducted with unlabeled or
[35S]-labeled methionine in the translation
mixture, depending on the experiment. The protein concentration of the
rabbit reticulocyte lysate, determined by the Bradford method (46) with
BSA as standard, was about 5070 mg/ml.
In Vitro Hormone-Binding Assay
Reticulocyte lysates containing the wild-type or mutant hMRs
were diluted 2-fold with TEGWD buffer (20 mM sodium
tungstate and 1 mM dithiothreitol in TEG) and incubated for
30 min at 20 C with 10 nM
[3H]aldosterone. Nonspecific binding was
measured in a parallel experiment with a transcription and translation
in the reticulocyte lysate without receptor. Bound and free steroids
were separated by the dextran-charcoal method: 25 µl lysate were
stirred for 5 min with 50 µl 4% Norit A, 0.4% Dextran-T70 in TEG
buffer, and centrifuged at 4,500 x g for 5 min at 4 C.
Bound steroid was measured by counting the radioactivity of the
supernatant. Radioactivity was measured, in disintegrations per min, in
a liquid scintillation spectrometer (LKB, Rockville, MD)
after adding 5 ml OptiPhase HiSafe (counting efficiency
50%).
Hormone Binding in Whole Cells
COS-7 cells transiently transfected as described above were
incubated for 30 min at 20 C with 10 nM
[3H]aldosterone. The cells were rinsed twice
with 1 ml ice-cold PBS (pH 7.4), and bound steroids were extracted by
incubating the cells with 0.5 ml ethanol at 20 C for 30 min. The
radioactivity of the ethanol extracts was measured in a
LKB liquid scintillation spectrometer after adding 5 ml
OptiPhase HiSafe (counting efficiency
50%).
Steroid-Binding Characteristics at Equilibrium
Reticulocyte lysates containing the wild-type or mutant hMRs
were diluted 2-fold with ice-cold TEGWD buffer and incubated for 4
h at 4 C with [3H]aldosterone (0.1100
nM). Bound (B) and unbound (U) steroids were separated by
the dextran-charcoal method. The change in B as a function of U was
analyzed (47) and the dissociation constant at equilibrium
(Kd) calculated.
Kinetic Experiments
Reticulocyte lysates containing the wild-type or mutant hMRs
were diluted 2-fold with ice-cold TEGWD buffer and incubated with 10
nM [3H]aldosterone for 1 h at
20 C. The lysate was then divided in two. One half was kept at 20 C to
measure the stability of the [3H]aldosterone-MR
complexes, and the other was incubated with 10 µM
aldosterone for various times. After each incubation period, bound and
free steroid were separated by the charcoal dextran method. Parallel
incubations containing [3H]aldosterone plus a
1000-fold excess of unlabeled aldosterone were used to calculate the
nonspecific binding. The half-lives of the steroid-receptor complexes
(t1/2) were calculated from the equation
B(t)Ê = ÊB(0) e-(k-1t), where B(0)
and B(t) represent the specific steroid binding at times 0 and t of the
dissociation period. B(t) is corrected for the stability of steroid
binding at each dissociation time.
Sucrose Gradient Centrifugation
Samples were layered onto a 520% sucrose gradient prepared in
TEGW buffer, and the gradients were centrifuged in a VTi 65.2 rotor at
4 C for 1 h, 45 min at 365,000 x g. Three-drop
fractions were collected by piercing the bottom of each tube. Each
collected fraction was analyzed by electrophoresis. Aldolase (A, 7.9S)
and BSA (4.6S) were used as external sedimentation markers.
Limited Proteolytic Digestion of Translated hMR
[35S]-labeled wild-type or mutant hMRs
synthesized in vitro were incubated with or without
unlabeled aldosterone (10-7
M) for 10 min at 20 C. Chymotrypsin (20 µg/ml
or 150 µg/ml) was added to 9 µl
[35S]-labeled translation mix incubated with or
without aldosterone for various times at 20 C. Aliquots of the
digestion product (1 µl) were removed and mixed with 20 µl protein
loading buffer, boiled for 5 min, immediately loaded onto a 12.5%
SDS-polyacrylamide gel, and subjected to electrophoresis. The gels were
then fixed for 30 min in methanol/acetic acid/distilled water
(30:10:60), treated with Entensify Universal Autoradiography Enhancer,
dried, and autoradiographed at -80 C overnight.
Production of GST Fusion Proteins
The vectors pGEX2TK containing GST, GST fused with the RIP-140
amino acid sequence 683-1158 (GST-RIP-140), and GST fused with the
hTIF1
amino acid sequence 630854 (GST-hTIF1
) were provided by
V. Cavaillès (48). GST-SRC-1 encoding a fusion protein containing
GST and residues 570780 of hSRC-1 was provided by M. G. Parker
(49). GST and GST fusion proteins were expressed as described by Kaelin
et al. (50). Overnight cultures of Escherichia
coli expressing the recombinant GST plasmids were diluted in
Luria-Bertani medium (LB). Cultures at an absorbance at 600 nm of
0.81.2 were induced for 3 h with isopropyl
ß-D-thiogalactoside (0.1
mM final concentration). Bacteria were then
collected by centrifugation, suspended 1:10 in NETN (0.5% Nonidet P-40
(NP40), 1 mM EDTA, 20 mM
Tris-HCl, 100 mM NaCl, pH 8.0) containing
protease inhibitors. The suspension was sonicated and then centrifuged.
Protein concentration was estimated by the Bradford method, and the
bacterial proteins were separated by SDS-PAGE and visualized by
Coomassie blue staining.
GST Pull-Down Assays
An aliquot of crude bacterial extract (1 ml) containing GST fusion
proteins was incubated for 30 min at 4 C with 100 µl
glutathione-Sepharose beads, previously washed three times, in NETN
[final concentration 1:1 (vol/vol)]. The glutathione-Sepharose beads
were then washed three times with NETN. The wild-type and mutant hMRs
were transcribed, translated, and 35S-labeled in
rabbit reticulocyte lysate following the manufacturers instructions.
The resulting receptors were incubated without (ethanol: no hormone) or
with 1 µM aldosterone or progesterone for 10 min at 20 C
and then with the fusion proteins on glutathione-Sepharose beads for
1 h at 4 C. The beads were washed, suspended in 20 µl loading
buffer, boiled for 3 min, and analyzed by SDS-PAGE. Signals were
amplified with Entensify, and gels were autoradiographed at -80 C
overnight.
hMR Homology Model
The hMR-LBD homology model and the docking of the ligands were
prepared as previously described (40). Briefly, the hMR-LBD homology
model was generated by the Modeller package (version 4.0) (51) using
the hPR crystal structure as a template (G. Auzou, J. Fagart, A.
Souque, C. Hellal-Levy, J. M. Wurtz, D. Moras, and M. E.
Rafestin-Oblin, manuscript in preparation).
Aldosterone was docked manually in the pocket using the
probe-accessible and van der Waals volumes as guides; these volumes
were generated with VOIDOO (52). The side chains in the vicinity of the
ligand were positioned in favorable orientation using a rotamer library
of the O package (53). The Charmm package (QUANTA/CHARMM package,
Molecular Simulation, Inc., Burlington, MA) was used for all
calculations. The complex was energy minimized in 2000 steps with a
dielectric constant of 2, using the Powell procedure. During the
minimization process, the hydrogen bonds were defined by upper harmonic
distance restraints (60 kcal Å-2 force
constant), and the overall structure of the LBD was maintained by
harmonic position restraints (30 kcal Å-2 force
constant) of the C
atoms of residues defining the secondary
structure elements.
 |
ACKNOWLEDGMENTS
|
---|
We are grateful to M. G. Parker, V. Cavailles, H. Richard
Foy, and F. Gouilleux for providing plasmids. We would like to thank
A. T. Beggah for technical advice on the mutagenesis experiments
and M. G. Catelli for stimulating discussions and critically
reading the manuscript. We also thank O. Parkes for editorial
assistance.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Corresponding author: M. E. Rafestin-Oblin; INSERM U478, Faculté de médecine Xavier Bichat, B. P. 416, 16 rue Henri Huchard, 75870 Paris Cédex 18, France. E-mail: oblin{at}bichat.inserm.fr
This work was suported by INSERM (APEX 9834, MERO) and by the
Fondation pour la recherche medicale (C.H.L.).
Received for publication January 12, 2000.
Revision received April 13, 2000.
Accepted for publication April 27, 2000.
 |
REFERENCES
|
---|
-
Evans RM 1988 The steroid and thyroid hormone receptor
superfamily. Science 240:889895[Medline]
-
Tsai MJ, OMalley BW 1994 Molecular mechanism of action of
steroid/thyroid receptor superfamily. Annu Rev Biochem 63:451486[CrossRef][Medline]
-
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G,
Umesono 3 K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835839[Medline]
-
Ribeiro RCJ, Kushner PJ, Baxter JD 1995 The nuclear hormone
receptor gene superfamily. Annu Rev Med 46:443453[CrossRef][Medline]
-
Pratt WB, Toft DO 1997 Steroid receptor interactions with
heat shock protein and immunophilin chaperones. Endocr Rev 18:306360[Abstract/Free Full Text]
-
Trapp T, Holsboer F 1995 Ligand-induced conformational
changes in the mineralocorticoid receptor analyzed by protease mapping.
Biochem Biophys Res Commun 215:28629[CrossRef][Medline]
-
Couette B, Fagart J, Jalaguier S, Lombès M, Souque A,
Rafestin-Oblin ME 1996 Ligand-induced conformational change in the
human mineralocorticoid receptor occurs within its hetero-oligomeric
structure. Biochem J 315:421427[Medline]
-
Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa
R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated
by a nuclear receptor co-repressor. Nature 377:397404[CrossRef][Medline]
-
Chen JD, Evans RM 1995 A transcriptional co-repressor that
interacts with nuclear hormone receptors. Nature 377:454457[CrossRef][Medline]
-
Schibata H, Spencer TE, Onate SA, Jenster G Tsai Sy, Tsai Mj,
Omalley BW 1997 Role of co-activators and co-repressors in the
mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 52:141165[Medline]
-
Torchia J, Glass C, Rosenfeld MG 1998 Co-activators and
co-repressors in the integration of transcriptional response. Curr Opin
Cell Biol 10:373383[CrossRef][Medline]
-
Bourguet W, Ruff M, Chambon P, Gronmeyer H, Moras, D 1995 Crystal structure of the ligand-binding domain of the human nuclear
receptor RXR-
. Nature 375:377382[CrossRef][Medline]
-
Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H,
Moras D 1995 Crystal structure of the RAR-gamma ligand-binding domain
bound to all-trans retinoic acid. Nature 378:681689[CrossRef][Medline]
-
Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD,
Fletterick RJ 1995 A structural role for hormone in the thyroid hormone
receptor. Nature: 378:690697[CrossRef][Medline]
-
Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T,
Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor.
Nature 389:753758[CrossRef][Medline]
-
Williams SP, Sigler PB 1998 Atomic structure of progesterone
complexed with its receptor. Nature 393:392396[CrossRef][Medline]
-
Tanenbaum DM, Wang Y, Williams SP, Sigler PB 1998 Crystallographic comparison of the estrogen and progesterone
receptors ligand binding domains. Proc Natl Acad Sci USA 95:59986003[Abstract/Free Full Text]
-
Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokaw
AR, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding
and co-activator assembly of the peroxisome proliferator-activated
receptor-
. Nature 395:137143[CrossRef][Medline]
-
Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D,
Gronemeyer H 1996 A canonical structure for the ligand-binding domain
of nuclear receptors. Nat Struct Biol 3:8794[Medline]
-
Moras D, Gronemeyer H 1998 The nuclear receptor ligand
-binding domain: structure and function. Curr Opin Cell Biol 10:384391[CrossRef][Medline]
-
Couette B, Jalaguier S, Hellal-Levy C, Lupo B, Fagart J, Auzou
G, Rafestin-Oblin ME 1998 Folding requirements of the ligand-binding
domain of the human mineralocorticoid receptor. Mol Endocrinol 12:855863[Abstract/Free Full Text]
-
Rafestin-Oblin ME, Couette B, Radanyi C, Lombès M,
Baulieu EE 1989 Mineralocorticoid receptor of the chick intestine.
Oligomeric structure and transformation. J Biol Chem 264:93049309[Abstract/Free Full Text]
-
Souque A, Fagart J, Coette B, Davioud E, Sobrio F, Marquet A,
Rafestin-Oblin ME 1995 The mineralocorticoid activity of progesterone
derivates depends on the nature of the C18 substituent. Endocrinology 136:56515658[Abstract]
-
Onate A, Tsai SY, Tsai MJ, OMalley BW 1995 Sequence and
characterization of a coactivator for the steroid hormone receptor
suparfamily. Science 270:13541357[Abstract]
-
Cavailles V, Dauvois S, Danielan PS, Parker MG 1994 Interaction of proteins with transcriptionally active estrogen
receptors. Proc Natl Acad Sci USA 91:1000910013[Abstract/Free Full Text]
-
Thenot S, Henriquet C, Rochefort H, Cavailles V 1997 Differential interaction of nuclear receptors with putative human
transcriptional coactivator hTIF1. J Biol Chem 272:1206212068[Abstract/Free Full Text]
-
Hong H, Kohli K, Garabedian MJ, Stallcup MR 1997 GRIP1, a
transcriptional coactivator for the AF-2 transactivation domain of
steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17:27352744[Abstract]
-
Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ,
Stallcup MR 1998 Nuclear receptor-binding sites of coactivators
glucocorticoid receptor interacting protein 1 (GRIP1) and steroid
receptor coactivator 1 (SRC-1): multiple motifs with different binding
specificities. Mol Endocrinol 12:302313[Abstract/Free Full Text]
-
Zhou ZX, Lane MV, Kemppainen JA, French FS Wilson EM 1995 Specificity of ligand-dependent androgen receptor
stabilization:receptor domain interactions influence ligand
dissociation and receptor stability. Mol Endocrinol 9:208218[Abstract]
-
Roux S, Terouanne B, Couette B, Rafestin-Oblin ME Nicolas JC 1999 Conformational change in the human glucocorticoid receptor induced
by ligand binding is altered by mutation of isoleucine 747 by a
threonine. J Biol Chem 274:1005910065[Abstract/Free Full Text]
-
Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P,
Heery D, Gronemeyer H, Chambon P, Losson R 1995 The N-terminal part of
TIF1, a putative mediator of the ligand-dependent activation function
(AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein
T18. EMBO J 14:20202033[Abstract]
-
Cavaillès V, Dauvois S, LHorset F, Lopez G, Hoare S,
Kushner PJ, Parker MG 1995 Nuclear factor RIP140 modulates
transcriptional activation by the estrogen receptor. EMBO J 14:37413751[Abstract]
-
Voegel JJ, heine MJ, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent
activation function AF-2 of nuclear receptors. EMBO J 14:36673675
-
Joyeux A, Cavaillès V, Balaguer P, Nicolas JC 1997 RIP140 enhances nuclear receptor-dependent transcription in
vivo in yeast. Mol Endocrinol 11:193220[Abstract/Free Full Text]
-
Collingwood TN, Rajanayagam O, Adams M, Wagner R,
Cavaillès V, Kalkhoven E, Matthews C, Nystrom E, Stenlof K,
Lindstedt G, Tisell L, Fletterick RJ, Parker MG 1997 A natural
transactivation mutation in the thyroid hormone ß receptor:
impaired interaction with putative transcriptional mediators. Proc Natl
Acad Sci USA 94:248253[Abstract/Free Full Text]
-
Masuyama H, Brownfield M, St-Arnaud R, MacDonald PN 1997 Evidence for ligand-dependent intramolecular folding of the AF-2 domain
in vitamin D receptor-activated transcription and coactivator
interaction. Mol Endocrinol 11:15071517[Abstract/Free Full Text]
-
Henttu PMA, Kalkhoven E, Parker MG 1997 AF-2 activity and
recruitement of steroid receptor coactivator 1 to the estrogen receptor
depend on a lysine residue conserved in nuclear receptors. Mol Cell
Biol 18321839
-
Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa
R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding
and coactivateur assembly of the peroxisome proliferator-activated
receptor-
. Nature 395:137143[CrossRef][Medline]
-
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA,
Greene GL 1998 The structural basis of estrogen receptor/coactivator
recognition and the antagonism of this interaction by tamoxifen. Cell 95:927937[Medline]
-
Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D,
Rafestin-Oblin ME 1999 Antagonism in the human mineralocorticoid
receptor. EMBO J 17:33173325[Abstract/Free Full Text]
-
Ribeiro RCJ, Apriletti JW, Wagner RL, Feng W, Kushner PJ,
Nilsson S, Scanlan TS, West BL, Fletterick RJ, Baxter JD 1998 X-ray
crystallographic and functional studies of thyroid hormone receptor. J
Steroid Biochem Mol Biol 65:133141[CrossRef][Medline]
-
Gouilleux F, Sola B, Couette B Richard-Foy H 1991 Cooperation
between structural elements in hormono- regulated transcription
from the mouse mammary tumor virus promoter. Nucleic Acids Res 19:15631569[Abstract]
-
Nelson RM, Long GL 1989 A general method of site-specific
mutagenesis using a modification of the thermus aquaticus polymerase
chain reaction. Anal Biochem 180:147151[Medline]
-
De Wet JR, Wood KV, Deluca M, Helsinki DR Subramani S 1987 Firefly luciferase gene: structure and expression in mammalian cells.
Mol Cell Biol 7:725737[Medline]
-
Herbomel P, Bourachot B Yanif M 1984 Two distinct enhancers
with different cell specificities coexist in the regulatory region of
polyoma. Cell 39:653662[Medline]
-
Bradford MM 1976 A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the principle
of protein-dye binding. Anal Biochem 72:248254[CrossRef][Medline]
-
Claire M, Rafestin-Oblin ME, Michaud A, Corvol P, Venot A,
Roth-Meyer C, Boisvieux JF Mallet A 1978 Statistical test of models and
computerized parameter estimation for aldosterone binding in rat
kidney. FEBS Lett 88:295299[CrossRef][Medline]
-
Thénot S, Henriquet C, Rochefort H, Cavaillès V 1997 Differential interaction of nuclear receptors with the putative
transcriptional coactivator hTIF1. J Biol Chem 272:1206212068[Abstract/Free Full Text]
-
Kalkhoven E, Valentine JE, Heery DM, Parker MG 1998 Isoforms
of steroid receptor co-activator 1 differ in their ability to
potentiate transcription by the oestrogen receptor. EMBO J 17:232243[Abstract/Free Full Text]
-
Kaelin WG, Pallas DC, DeCaprio JA, Kaye FJ, Livingston DM 1991 Identification of cellular proteins that can interact specifically with
the T/E1A-binding region of the retinoblasma gene product. Cell 64:521532[Medline]
-
Sali A, Blundell TL 1993 Comparative protein modelling by
satisfaction of spatial restraints. J Mol Biol 234:779815[CrossRef][Medline]
-
Kleywegt, GJ, Jones TA 1994 Detection, delineation,
measurement and display of cavities in macromolecular structures. Acta
Crystallogr D50:178185
-
Jones TA, Zou JY, Cowan SW, Kjeldgaard M 1991 Improved methods for binding protein models in electron density maps
and the location of errors in these models. Acta Crystallogr
A7:110119
-
Barton GJ 1993 ALSCRIPT: a tool to format multiple sequence
alignments. Protein Eng 6:3740[Medline]
-
Evans SV 1993 SETOR: hardware lighted three-dimensional solid
model representations of macromolecules. J Mol Graphics 11:134138[CrossRef][Medline]